leisure time -WSS

leisure time

author：leisure time 2025-09-07 06:46:43 - browse：566

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： HIV vaccine remains elusive. Immunologists keep trying new ideas

WSS

HIV vaccine remains elusive. Immunologists keep trying new ideas

Medicare to cover more brain scans for Alzheimer’s patients

Why hospitals are withdrawing from US News rankings

When prostate cancer spreads, where it goes matters

HIV vaccine remains elusive. Immunologists keep trying new ideas

Custom gene therapy hints at new path for rare disease treatments

hotspot

leisure time

explore

Heart attack and stroke risk calculators need revising

Arc Institute generative AI designs new CRISPR systems

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Second House panel advances two

Cancer drug shortages should be causing more outrage

Case highlights the risks of experimental stem cell therapy

Hollywood unions extend contract negotiations for actors

Cosmetics set for new safety regulation. Why the industry is on board

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

At Orexo, a ‘turning point’ for everything but digital health

entertainment

Case highlights the risks of experimental stem cell therapy

Addiction experts warn against a second 'war on drugs'

Startup Neumora takes a novel depression drug to Phase 3

AI can’t replace a physician’s gut feeling

Cosmetics set for new safety regulation. Why the industry is on board

HIV vaccine remains elusive. Immunologists keep trying new ideas

leisure time

leisure time

hotspot

focus